Compare Novartis AG (NVS) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs PepsiCo, Inc. — how do they compare? Novartis AG trades at $142.74 (market cap $268.57B), while PepsiCo, Inc. trades at $127.99 (market cap $174.89B). The key difference: Novartis AG is the larger of the two by market cap, and PepsiCo, Inc. pays the higher dividend (4.61%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and PepsiCo, Inc. for 107 Days on average.
| NVS | PEP | |
|---|---|---|
Market Cap | $268.57B | $174.89B |
Volume | 1,532,573 | 23,968,864 |
Sector | Health | Consumer Staples |
52-Week High | $168.62 | $170.44 |
52-Week Low | $121.80 | $123.64 |
Typical Hold Time | 82 Days | 107 Days |
Enterprise Value | $309.89B | $215.61B |
Dividend Yield | 3.31% | 4.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
PepsiCo (PEP) trades at $123.64, down 1.65% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS of $2.34 surpassing the $2.29 expectation. Revenue reached $93.93B in 2025, though net income margin dipped to 8.77%. Recent news highlights price cuts on snacks like Doritos to address consumer pushback on high prices.
The outlook is mixed: strong profitability metrics like a 51.59% ROE and a consensus analyst price target of $146.77 suggest upside potential, but competitive pressures and recent net margin compression pose risks. Institutional activity shows mixed signals with some firms increasing stakes while others reduce holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
